GCC Myasthenia Gravis Payer & HTA

Generalised MG has no formal NPHC coverage programme, unlike SMA or PNH. Access to novel agents, efgartigimod (Vyvgart) and, rarely, eculizumab (Soliris), runs through three channels: individual hospital pharmacy committee (HPC) approval requiring MGFA Class III-IV disease, failure of two or more immunosuppressive therapy regimens, and AChR-antibody-positive documentation; private VHI pre-authorisation, fastest in the UAE under mandatory insurance law (1-4 weeks); or an NPHC special application with no formally defined pathway, assessed case-by-case. Efgartigimod, SFDA- and UAE MOH-registered in 2023, is accessible at KFSH&RC, AUH, and HMC via specialist prescription plus insurance or NPHC prior authorisation; an estimated 200-300 GCC patients were on therapy as of mid-2024. Eculizumab is technically available for MG, since its existing PNH SFDA registration covers the indication, but is rarely prescribed because PNH coverage criteria do not automatically extend to MG, requiring a separate individual NPHC application.

Efgartigimod's IV induction cycle (four infusions) costs SAR 80,000-100,000 in the GCC, against a US WAC equivalent above SAR 300,000 per cycle; annual maintenance at four to six cycles per year runs SAR 300,000-600,000. The subcutaneous formulation (Vyvgart Hytrulo) costs roughly 80% of the IV price and is preferred by patients for home self-injection. Private insurers are building formal PA criteria: Bupa Arabia's 2023 policy requires AChR-antibody-positive generalised MG, MGFA Class III-IV, failure of at least two immunosuppressive lines (azathioprine and mycophenolate mofetil), and a documented MGFA-TC composite score of 3 or higher, with an approval rate of 60-70%. HAAD Abu Dhabi's DRG-based government-hospital reimbursement already includes biologics for refractory MG. The NPHC application route sets a materially higher bar: MGFA Class IV or myasthenic crisis plus at least three failed immunosuppressive lines. argenx is actively pursuing NPHC engagement, with routine NPHC coverage estimated for 2025-2026, the access catalyst this market is waiting on.

This assessment is built from argenx GCC market access documentation, Bupa Arabia and HAAD Abu Dhabi PA criteria, and NPHC programme scope documentation covering GCC MG access.

Key sources: argenx GCC market access documentation (2024); NPHC programme scope; Bupa Arabia formulary and PA criteria (2023); HAAD DRG classification (UAE, 2023); argenx GCC pricing data (2024); GCC private insurance MG PA data.